Europe Viscosupplementation Market Size & Share Analysis - Growth, Trends, And Forecasts (2025 - 2030)

The Europe Viscosupplementation Market Report is Segmented by Dosage (Single Injection, Three Injections, and Five Injections), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (Germany, The United Kingdom, France, Italy, Spain, and Rest of Europe). The Report Offers the Value (USD) for all the Above Segments.

Europe Viscosupplementation Market Size

Compare market size and growth of Europe Viscosupplementation Market with other markets in Healthcare Industry

Europe Viscosupplementation Market Analysis

The Europe Viscosupplementation Market size is estimated at USD 1.27 billion in 2025, and is expected to reach USD 1.74 billion by 2030, at a CAGR of 6.5% during the forecast period (2025-2030).

The viscosupplementation market in Europe is experiencing significant growth, primarily driven by the increasing prevalence of osteoarthritis and the introduction of advanced and combination products. Joint injuries resulting from road accidents, such as dislocations, ligament tears, and cartilage damage, often lead to severe orthopedic conditions. According to data from Versus Arthritis published in May 2023, over 10 million individuals in the United Kingdom suffer from arthritis annually, equating to one in six people facing pain, fatigue, and mobility challenges. This high incidence of joint-related conditions underscores the growing demand for effective treatment solutions, thereby creating opportunities for market expansion. Consequently, the rising burden of orthopedic diseases linked to accidents is expected to significantly contribute to the growth of the viscosupplementation market in the region.

Osteoarthritis (OA), a condition predominantly affecting older adults, is becoming increasingly common due to Europe's aging population. This demographic shift is driving the need for effective treatments to manage joint pain and improve mobility. The World Economic Forum, in its September 2023 report, projected that the old-age dependency ratio in Europe would rise from 36% in 2023 to approximately 59% by 2070. Additionally, the European Commission's November 2023 report forecasted that by 2100, over 30% of the EU's population would be aged 65 or older, with nearly half a million centenarians by 2050. Modern lifestyle factors, including sedentary habits and obesity, further exacerbate joint stress and OA prevalence. This growing demand for viscosupplementation treatments highlights the market's potential for sustained growth. As a result, the aging population and lifestyle-related factors are expected to remain key drivers of market expansion.

Strategic initiatives by market players, such as product launches, partnerships, mergers, acquisitions, and collaborations, are further enhancing the availability of innovative products and strengthening competitive positioning. For instance, in May 2023, BioSenic Paris reacquired global IP rights and announced updates on the development of JTA-004, an injectable viscosupplement designed to address a specific subtype of knee osteoarthritis with combined anti-pain and anti-inflammatory properties. Such developments underscore the industry's commitment to innovation and its focus on addressing unmet medical needs. Consequently, these strategic activities are anticipated to play a pivotal role in driving the market's growth by fostering innovation and expanding product offerings.

In conclusion, the viscosupplementation market in Europe is poised for growth, driven by the increasing prevalence of osteoarthritis, an aging population, and strategic initiatives by market players. However, challenges such as regulatory barriers and limited awareness of viscosupplementation treatments may pose obstacles to market expansion.

Europe Viscosupplementation Industry Overview

Europe’s viscosupplementation market is semi-consolidated, with major players adopting various business strategies such as partnerships, product launches, approvals, and collaboration to maintain their market position. Some of the key market players include Anika Therapeutics Inc., Bioventus LLC, Ferring Pharmaceuticals, Fidia Farmaceutici SpA, Sanofi SA, Johnson & Johnson Services Inc., and Zimmer Biomet.

Europe Viscosupplementation Market Leaders

  1. Ferring Pharmaceuticals

  2. Fidia Farmaceutici s.p.a.

  3. Zimmer Biomet Holdings

  4. OrthogenRx Inc.

  5. Sanofi SA

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

Europe Viscosupplementation Market News

  • February 2024: IBSA UK introduced SINOVIAL, an advanced formulation targeting musculoskeletal conditions, leveraging its proprietary technology.
  • March 2023: BioSenic revealed a re-evaluation of the results from its Phase III trial for JTA-004, an enhanced viscosupplement aimed at treating knee osteoarthritis (OA).

Europe Viscosupplementation Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Osteoarthritis and Growing Aging Population
    • 4.2.2 Introduction of Advanced and Combination Products
  • 4.3 Market Restraints
    • 4.3.1 Regulatory Issues and Lack of Awareness
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Dosage
    • 5.1.1 Single Injection
    • 5.1.2 Three Injections
    • 5.1.3 Five Injections
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Others (Specialty Clinics, and Rehabilitation Centers, Among Others)
  • 5.3 Geography
    • 5.3.1 Germany
    • 5.3.2 United Kingdom
    • 5.3.3 France
    • 5.3.4 Italy
    • 5.3.5 Spain
    • 5.3.6 Rest of Europe

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Anika Therapeutics Inc.
    • 6.1.2 Bioventus LLC
    • 6.1.3 Chugai Pharmaceuticals Co. Ltd (Roche)
    • 6.1.4 Ferring Pharmaceuticals
    • 6.1.5 Fidia Farmaceutici s.p.a.
    • 6.1.6 Zimmer Biomet Holdings
    • 6.1.7 OrthogenRx Inc.
    • 6.1.8 Sanofi SA
    • 6.1.9 Seikagaku Corporation
    • 6.1.10 Aptissen
    • 6.1.11 Johnson & Johnson Services Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, SWOT Analysis, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Europe Viscosupplementation Industry Segmentation

Viscosupplements are injections of hyaluronic acid for diarthrodial joints, intending to restore the rheological properties of the synovial fluid, thereby producing analgesia, mechanical, chondroprotective, and anti-inflammatory effects. Viscosupplements are usually preferred by healthcare providers to treat osteoarthritis. They may also benefit patients with certain other kinds of arthritis, such as rheumatoid arthritis.

Europe's viscosupplementation market is segmented by dosage, end user, and geography. By dosage, the market is segmented into single injections, three injections, and five injections. By end user, the market is segmented into hospitals, ambulatory surgical centers, and others. Other end users include specialty clinics, and rehabilitation centers, among others. By geography, the market is segmented into Germany, the United Kingdom, France, Italy, Spain, and Rest of Europe. The report offers the value (USD) for all the above segments.

By Dosage Single Injection
Three Injections
Five Injections
By End User Hospitals
Ambulatory Surgical Centers
Others (Specialty Clinics, and Rehabilitation Centers, Among Others)
Geography Germany
United Kingdom
France
Italy
Spain
Rest of Europe
By Dosage
Single Injection
Three Injections
Five Injections
By End User
Hospitals
Ambulatory Surgical Centers
Others (Specialty Clinics, and Rehabilitation Centers, Among Others)
Geography
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region or Segment?
Customize Now

Europe Viscosupplementation Market Research FAQs

How big is the Europe Viscosupplementation Market?

The Europe Viscosupplementation Market size is expected to reach USD 1.27 billion in 2025 and grow at a CAGR of 6.5% to reach USD 1.74 billion by 2030.

What is the current Europe Viscosupplementation Market size?

In 2025, the Europe Viscosupplementation Market size is expected to reach USD 1.27 billion.

Who are the key players in Europe Viscosupplementation Market?

Ferring Pharmaceuticals, Fidia Farmaceutici s.p.a., Zimmer Biomet Holdings, OrthogenRx Inc. and Sanofi SA are the major companies operating in the Europe Viscosupplementation Market.

What years does this Europe Viscosupplementation Market cover, and what was the market size in 2024?

In 2024, the Europe Viscosupplementation Market size was estimated at USD 1.19 billion. The report covers the Europe Viscosupplementation Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Viscosupplementation Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Page last updated on: December 20, 2024

Europe Viscosupplementation Industry Report

Statistics for the 2025 Europe Viscosupplementation market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Viscosupplementation analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.